May 14, 2020
Jazz Pharmaceuticals to Showcase New Data From its Growing Oncology Portfolio at Virtual ASCO and EHA 2020 Meetings
Apr 21, 2020
Jazz Pharmaceuticals to Report 2020 First Quarter Financial Results on May 5, 2020
Mar 31, 2020
Jazz Pharmaceuticals Provides COVID-19 Business Update
Mar 25, 2020
Jazz Pharmaceuticals Announces FDA Acceptance of New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
Feb 17, 2020
PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer
Feb 11, 2020
SYLVANT® (siltuximab) Recommended by the National Comprehensive Cancer Network® (NCCN®) Guidelines as a Preferred Treatment Option for Patients with Idiopathic Multicentric Castleman Disease (iMCD) for Patients with Plasmacytic or Mixed Histology
Feb 11, 2020
Jazz Pharmaceuticals to Report 2019 Fourth Quarter and Full Year Financial Results on February 25, 2020
Jan 22, 2020
PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period
Dec 19, 2019
PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S.
Nov 07, 2019
Jazz Pharmaceuticals to Highlight Growing Hematology Oncology Pipeline at ASH 2019 Annual Meeting
Sep 25, 2019
Jazz Pharmaceuticals Presents Positive JZP-258 Phase 3 Study Data at World Sleep 2019
Aug 12, 2019
Jazz Pharmaceuticals Announces Acquisition of Cavion, Inc.
Jun 03, 2019
Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development
May 29, 2019
EUSA Pharma Announces New QARZIBA(R) (Dinutuximab beta) Data to Be Presented at 2019 ASCO Annual Meeting
May 16, 2019
Jazz Pharmaceuticals to Present New Data at Upcoming ASCO Annual Meeting and EHA Congress
May 15, 2019
EUSA Pharma Announces Appointment of Carsten Thiel as President Europe and Darrel P. Cohen as Head of Clinical Development
May 09, 2019
Jazz Pharmaceuticals Data to Showcase Ongoing Sleep Medicine Research at SLEEP 2019
Mar 26, 2019
Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness
Mar 20, 2019
Jazz Pharmaceuticals Announces U.S. FDA Approval of Sunosi(TM) (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Feb 14, 2019
Jazz Pharmaceuticals Announces Appointment of Anne O'Riordan to its Board of Directors